Roche Ticlid-Associated TTP Could Be 1 in 2,000-4,000 Patients - Labeling
"The incidence of ticlopidine-associated [thrombotic thrombocytopenic purpura] may be as high as one case in every 2,000 to 4,000 patients exposed," new language in a boxed warning for Roche's Ticlid states.
You may also be interested in...
Roche is "revisiting" its safety evaluation processes for new drugs following the worldwide withdrawal of Posicor (mibefradil) and the European suspension of Tasmar (tolcapone) in the second half of 1998, Roche CEO Franz Humer said during the firm's annual financial results meeting in Basel, Switzerland on March 30.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011